Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II single-arm study of delgocitinib ointment for dermatomyositis skin symptoms
jRCTs031230077Phase 2Recruiting
- Start
- Feb 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of delgocitinib in dermatomyositis (DM). Primary endpoint: Improvement rate of skin rash at 8 weeks. Started Feb 2024; status: recruiting.
02
Drugs
delgocitinib
03
Conditions
dermatomyositis (DM)
Beyond the preview
Go deeper on jRCTs031230077.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031230077.